Henry Schein, Inc.
HSIC Healthcare Medical Distribution
Henry Schein, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $13.2 billion, up 4.03% from fiscal 2024. In the quarter to June 2026, revenue grew 6.73%, EPS grew 16.9%, free cash flow grew 140.9% and total debt rose 15.2%, each against the same quarter a year earlier. Member of the S&P 500; insiders bought in the last twelve months.
Follow HSIC
Henry Schein, Inc. (HSIC) P/E ratio
As of 16 October 2026, Henry Schein, Inc. (HSIC) trades at a P/E ratio of 25.0×. Over the past ten years it has ranged from 9.1× (March 2020) to 31.7× (November 2024); the current reading is higher than 91% of that period. That is above the Healthcare sector median of 23.0×.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 22.9× | 1.61% |
| FY2024 | 22.5× | (5.14%) |
| FY2023 | 23.8× | 17.31% |
| FY2022 | 20.3× | 17.56% |
| FY2021 | 17.2× | (27.07%) |
| FY2020 | 23.6× | 67.49% |
| FY2019 | 14.1× | (19.37%) |
| FY2018 | 17.5× | (19.79%) |
| FY2017 | 21.8× | 11.63% |
| FY2016 | 19.5× | (8.99%) |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Jun 2026 | 24.1× | 9.39% |
| Mar 2026 | 22.1× | (3.65%) |
| Dec 2025 | 22.9× | 10.08% |
| Sep 2025 | 20.8× | (10.57%) |
| 42 more quarters | Free account |
Against its own ten years
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| ACH Accendra Health, Inc. compare | n/m |
| FOCL FocalTherics compare | n/m |
| AHG Akso Health Group Sponsored ADR compare | n/m |
| COSM Cosmos Health Inc. compare | n/m |
| HSIC Henry Schein, Inc. | 25.0× |
| COR Cencora, Inc. compare | 25.2× |
| MCK McKesson Corporation compare | 26.8× |
| CAH Cardinal Health, Inc. compare | 35.0× |
| HKPD Cellyan Biotechnology Co., Ltd compare | — |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)
More on HSIC
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement